Legend Biotech (LEGN) Total Non-Current Liabilities (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Total Non-Current Liabilities data on file, last reported at $119.9 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 67.02% year-over-year to $119.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.9 million (down 67.02% YoY) and the FY2025 annual result came in at $95.2 million, down 72.95% from the prior year.
• Total Non-Current Liabilities improved to $119.9 million in Q1 2026, from $95.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $388.9 million in Q2 2025 to a low of $95.2 million in Q4 2025.
• A 5-year average of $310.2 million and a median of $344.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 143102.85% — and 2025, when it sank 72.95%.
• Tracing LEGN's Total Non-Current Liabilities over 5 years: stood at $288.9 million in 2022, then soared by 31.83% to $380.8 million in 2023, then fell by 7.59% to $351.9 million in 2024, then slumped by 72.95% to $95.2 million in 2025, then advanced by 25.95% to $119.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $119.9 million (Q1 2026), $95.2 million (Q4 2025), and $268.1 million (Q3 2025), per Business Quant data.